Printer Friendly

DISEASE DETECTION INTERNATIONAL GRANTED CANADIAN PATENT FOR RAPID TEST DEVICE AND METHODS

 DISEASE DETECTION INTERNATIONAL GRANTED CANADIAN PATENT
 FOR RAPID TEST DEVICE AND METHODS
 IRVINE, Calif., Oct. 26 /PRNewswire/ -- Disease Detection International Inc. ("DDI") (OTC Bulletin Board) announced today that the company has received notice of allowance of its Canadian Patent Application related to the company's SeroCard(R) and ImmunoCard(R), rapid diagnostic test kits. The patent granted in Canada provides additional international protection for the company's products produced under its U.S. patent granted in April of 1991.
 DDI's president and chief executive officer, H. Thad Morris, stated that the additional patent coverage is significant in that the company's rapid diagnostic test kits used to detect the presence of specific antibodies in blood using unmanipulated whole blood from a simple finger prick, are the only whole blood, enzyme-linked immunoassays (ELISAs) currently available. Heretofore, all ELISA tests required serum or plasma derived from veinipuncture (drawing of blood from a vein by a skilled technologist) and centrifugation (spinning of tubes of blood to separate the serum or plasma components from red blood cells).
 In 1988 and 1990, the company received U.S. Food and Drug Administration (FDA) 510(k) approval to market four rapid tests for infectious and sexually transmitted diseases produced under its patented materials and methods. Currently, the company sells rapid, seven-minute ELISA tests to detect antibodies to toxoplasma, herpes, rubella and cytomegalovirus.
 In a separate announcement, Disease Detection International detailed its submission of an Investigational New Drug (IND) application seeking FDA approval to commence formal clinical studies for its SeroCard(R) HIV-1 test produced under the same patents.
 Morris further stated that the company has previously filed additional international patent applications in Europe and Japan and has granted an exclusive license to Trinity Biotech plc., an Irish company. In exchange for $1 million in cash and a continuing royalty, DDI granted Trinity worldwide rights to the company's patents and related technology in the field of AIDS and other sexually transmitted diseases. Trinity Biotech will manufacture and market DDI's blood tests outside the United States and Canada in addition to developing rapid tests on the SeroCard which use saliva as a specimen. DDI will have the exclusive marketing rights in the United States and Canada for both blood and saliva tests developed by Trinity.
 Disease Detection International Inc. develops, manufactures and markets rapid diagnostic tests for infectious and sexually transmitted diseases as well as rapid tests for pregnancy and ovulation prediction.
 -0- 10/26/92
 /CONTACT: H. Thad Morris, president and CEO of Disease Detection International, 714-457-1787/ CO: Disease Detection International Inc. ST: California IN: MTC SU:


JL -- NYON5 -- 4590 10/26/92 09:16 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 26, 1992
Words:435
Previous Article:DISEASE DETECTION INTERNATIONAL FILES 'IND' APPLICATION WITH FDA SEEKING APPROVAL TO BEGIN FORMAL CLINICAL STUDIES FOR SEVEN-MINUTE AIDS TEST
Next Article:AIRBORNE FREIGHT CORP. REPORTS THIRD-QUARTER 1992 RESULTS
Topics:


Related Articles
DISEASE DETECTION INTERNATIONAL INC. AND SALIVA RESEARCH LTD. SIGN EQUITY FINANCING, AND TECHNOLOGY SALE AND MARKETING AGREEMENTS
DISEASE DETECTION INTERNATIONAL FILES 'IND' APPLICATION WITH FDA SEEKING APPROVAL TO BEGIN FORMAL CLINICAL STUDIES FOR SEVEN-MINUTE AIDS TEST
DISEASE DETECTION INTERNATIONAL SEEKS INJUNCTION AGAINST EDITEK
PRELIMINARY INJUNCTIONS GRANTED TO PRESERVE STATUS QUO PENDING ARBITRATION OF PATENT LICENSE DISPUTE BETWEEN DISEASE DETECTION INTERNATIONAL AND...
DISEASE DETECTION INTERNATIONAL TO SUPPLY 1.2 MILLION TESTS IN BRASILIAN FEDERAL AIDS PROGRAM FOR THE STATE OF SAO PAULO, BRASIL
OPTICAL IMMUNOASSAY PATENT GRANTED TO BIOSTAR INC.; BOULDER-BASED FIRM HOLDS ALL OIA PATENTS ISSUED IN THE U.S.
Multiple Patents Issued to Biostar, Inc.; Boulder Firm's Patents Strengthen Proprietary Technology
Boston Biomedica awarded United States patent for extraction of nucleic acids from cells using pressure cycling technology.
Avitar receives approval on Oralscreen collector patent.
Cepheid awarded patents for ultrasonic lysis and sample preparation technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters